Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
View Top Employees from Eloxx PharmaceuticalsWebsite | http://www.eloxxpharma.com |
Ticker | SVON |
Revenue | $7 million |
Funding | $350000 |
Employees | 21 (21 on RocketReach) |
Founded | 2013 |
Address | 480 Arsenal Way Suite 130, Watertown, Massachusetts 02472, US |
Phone | (781) 557-5300 |
Technologies |
JavaScript,
HTML,
PHP
+35 more
(view full list)
|
Industry | Business Services, Biotechnology Research, Biotech, Rare Diseases, Power Conversion & Protection Equipment, Pharmaceuticals, Electronics, Drug Development, Manufacturing, Education, Life Sciences, Aerospace & Defense, Healthcare, Organizations |
Competitors | Aptahem, ChemoCentryx, Helix Biopharma Corp (HBPCF), Noveome Biotherapeutics, Inc., Synthetic Biologics, Inc. |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 33 Companies, NAICS Code 54171 Companies, NAICS Code 541711 Companies |
Looking for a particular Eloxx Pharmaceuticals employee's phone or email?
The Eloxx Pharmaceuticals annual revenue was $7 million in 2024.
Ali Hariri is the Chief Medical Officer of Eloxx Pharmaceuticals.
21 people are employed at Eloxx Pharmaceuticals.
Eloxx Pharmaceuticals is based in Watertown, Massachusetts.
The NAICS codes for Eloxx Pharmaceuticals are [541, 5417, 54, 33, 54171, 541711].
The SIC codes for Eloxx Pharmaceuticals are [873, 87].